Comprehensive HIV-1 Genotypic Drug Resistance Testing Solution

In China, the prevalence of HIV drug-resistant strains continues to increase. At the same time, drug resistance testing for low viral load samples (50–1000 copies/mL) remains challenging due to low amplification success rates. This limitation poses a major barrier to personalized treatment and effective disease control. IMPMM provides HIV-1 genotypic drug resistance testing services specifically optimized for low viral load samples, offering reliable analytical support for precision treatment decisions and long-term drug resistance monitoring.

Key Features

Broad Clinical Applications

Sample Types

Compatible with serum, plasma, whole blood, and dried blood spot (DBS) samples.

High Sensitivity

When HIV-1 RNA viral load exceeds 50 copies/mL, the overall success rate of drug resistance testing exceeds 95%.

Drug Resistance Coverage

Simultaneous detection of NRTI, NNRTI, PI, and INSTI gene regions, providing a comprehensive resistance profile for commonly used antiretroviral therapies.

Intelligent Interpretation

AI-assisted analysis supports accurate interpretation of complex mutation patterns and enables automated report generation.

Pre-Treatment Drug Resistance Testing

Treatment Failure Analysis

Resistance Monitoring for Treatment Optimization

Drug Resistance Assessment in Low-Level Viremia

Longitudinal Monitoring of Resistance Mutations

Early Detection of Archived Resistance